CN113952317A - 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 - Google Patents
一种血小板-dfo脂质体纳米颗粒、制备方法和应用 Download PDFInfo
- Publication number
- CN113952317A CN113952317A CN202111324986.4A CN202111324986A CN113952317A CN 113952317 A CN113952317 A CN 113952317A CN 202111324986 A CN202111324986 A CN 202111324986A CN 113952317 A CN113952317 A CN 113952317A
- Authority
- CN
- China
- Prior art keywords
- dfo
- liposome
- platelet
- buffer
- platesome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 47
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000012528 membrane Substances 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 24
- 230000000302 ischemic effect Effects 0.000 claims abstract description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 20
- 230000002537 thrombolytic effect Effects 0.000 claims abstract description 15
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 10
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 10
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 238000010253 intravenous injection Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000007922 nasal spray Substances 0.000 claims abstract description 4
- 229940097496 nasal spray Drugs 0.000 claims abstract description 4
- 239000006187 pill Substances 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 23
- 241000699670 Mus sp. Species 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 12
- 239000011534 wash buffer Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003146 anticoagulant agent Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 241000700159 Rattus Species 0.000 claims description 7
- 238000001125 extrusion Methods 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 230000000887 hydrating effect Effects 0.000 claims description 5
- 230000036571 hydration Effects 0.000 claims description 5
- 238000006703 hydration reaction Methods 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 238000004506 ultrasonic cleaning Methods 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 230000002429 anti-coagulating effect Effects 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 abstract description 11
- 208000014674 injury Diseases 0.000 abstract description 11
- 230000008499 blood brain barrier function Effects 0.000 abstract description 9
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 9
- 230000008685 targeting Effects 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 5
- 230000002093 peripheral effect Effects 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 239000006185 dispersion Substances 0.000 abstract description 3
- 238000013270 controlled release Methods 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract description 2
- 208000024248 Vascular System injury Diseases 0.000 abstract 1
- 208000012339 Vascular injury Diseases 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 42
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 32
- 229960000958 deferoxamine Drugs 0.000 description 32
- 229910052742 iron Inorganic materials 0.000 description 21
- 206010008118 cerebral infarction Diseases 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 18
- 208000006011 Stroke Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 230000010410 reperfusion Effects 0.000 description 12
- 230000002490 cerebral effect Effects 0.000 description 11
- 201000006474 Brain Ischemia Diseases 0.000 description 10
- 206010008120 Cerebral ischaemia Diseases 0.000 description 10
- 206010008190 Cerebrovascular accident Diseases 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000037906 ischaemic injury Diseases 0.000 description 6
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 208000029028 brain injury Diseases 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010065973 Iron Overload Diseases 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种血小板‑DFO脂质体纳米颗粒,其制备方法和应用。所述血小板‑DFO脂质体纳米颗粒为三层结构,中间层为脂质体,由大豆卵磷脂:胆固醇:mPEG‑DSPE‑2000按质量比(3‑4):2:1制备而成,用以包裹最内层铁螯合剂DFO,最外层包裹血小板膜,脂质体DFO与血小板的比例为1mL:1.0‑2.0×109个血小板的膜。本发明的血小板‑DFO脂质体纳米颗粒理化性质稳定、分散均一,具备长期保存稳定性和缓控释能力,能够穿越血脑屏障,具有靶向血管损伤区域的能力。其作为治疗缺血溶栓后的一种药物进行应用,制备成静脉注射液、胶囊、口服液、滴丸、喷鼻剂等剂型,可用于治疗各种器官血管堵塞疏通后对周围组织造成损伤的治疗。
Description
技术领域
本发明涉及一种血小板-DFO脂质体纳米颗粒,制备方法及其在靶向治疗脑缺血再灌注损伤的药物中的应用,属于生物工程技术领域。
背景技术
缺血性脑中风是一种由于脑部血管栓塞引起的神经系统疾病,因其高致残率、高复发率和高致死率成为全球范围内引起人类死亡的第二大病因。目前针对缺血性脑中风最有效的治疗方法是药物或机械溶栓。但溶栓后脑血流的瞬间恢复又会引起钙离子内流、炎症反应以及自由基积累,造成不可避免的、更为严重的二次损伤,即脑缺血再灌注损伤(Ischemic reperfusion, I/R)。由于难以透过血脑屏障(blood brain barrier, BBB)等原因,目前针对I/R损伤的药物还十分有限。因此,开发并制备能有效穿越BBB并靶向缺血损伤区的溶栓后治疗用药迫在眉睫。I/R损伤的病理机制较复杂,其中最重要的原因之一是大量活性氧自由基(Reactive oxygen species, ROS)在脑内过度积累,引起神经细胞的死亡,而脑铁过载是造成氧化应激损伤的关键因素。
铁是人体必不可少的微量元素,特别是脑作为高耗氧、高代谢活性的器官,有较高的铁含量。铁参与了脑内能量代谢、递质合成、突触构建、髓鞘形成等多种过程,是维持正常脑功能必不可少的成分。但是,脑铁过量时则会产生毒性作用。一方面铁可以通过芬顿反应促进自由基的形成;另一方面,铁可以作为酶的辅基催化脂质过氧化反应,促进脂质自由基的形成。随着研究的深入,越来越多的证据表明,铁依赖的ROS在缺血损伤区过量积累,使大量神经细胞发生铁死亡,是造成I/R脑内神经元丢失的重要原因。临床数据分析也发现,缺血性脑中风患者血清中铁蛋白含量与患者的损伤程度呈正相关。小鼠模型中,缺血损伤区的铁水平显著升高,且高铁饲养的小鼠在I/R损伤后表现出更严重的细胞死亡和运动功能障碍。因此,及时祛除I/R脑损伤区内过量的铁即可有效缓解脑损伤,改善治疗效果。
去铁胺(DFO)是一种临床上常用的铁螯合剂,与铁具有高亲和性,能治疗铁过载相关疾病,但由于其是亲水性药物,半衰期短,难以透过BBB,外周毒性大等特点,限制了其在治疗缺血性中风中的应用。如何将DFO有效递送至缺血损伤区抑制铁依赖的神经损伤,同时不影响正常脑区的铁水平成为临床上脑中风溶栓后治疗药物制备的重点与难点。因此,如何构建一种具有靶向性、高载药量、低毒、易穿越BBB的祛铁药物,用于有效治疗缺血性脑中风溶栓后,血流再灌注引起的二次神经损伤,成为亟需解决的课题。
发明内容
本发明的目的是提供一种血小板-DFO脂质体纳米颗粒,将DFO、大豆卵磷脂、胆固醇、mPEG-DSPE-2000和血小板按照一定比例制备而成,用于缺血性脑中风溶栓后神经损伤的治疗药物。
为解决上述问题,实现本发明的目的,本发明首先采用薄膜水化法将大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比(3-4):2:1的比例,制备了DFO脂质体(Liposome-DFO),DFO的含量为5-15mg/mL。脂质体是一种具备低毒性、长缓释性的药物载体,具有类似细胞膜的双分子层结构,无毒、无免疫原,可作为疏水性、亲水性或两性物质的载体,且纳米脂质体稳定性高,体外不易聚集,体内不易被巨噬细胞吞噬。根据脂质体的优势,制备的Liposome-DFO有效解决了DFO半衰期短、无法跨越BBB的问题。由于中风缺血区常伴有脑微血管损伤,而血小板能定向到受损血管并与之结合,因此血小板具有主动靶向缺血损伤区以及免疫逃逸的天然优势。利用血小板的这一优势,利用反复冻融法制备了血小板膜(PNV),随后按照1.0-2.0×109个血小板的膜与1 mL Liposome-DFO混合,用挤出器共挤出的方法,制备了Platesome-DFO,赋予了该纳米颗粒仿生化功能,解决了将纳米粒子准确靶向至脑中风缺血损伤区、提高药物浓度的问题。最后,以小鼠大脑中动脉内线栓阻断法MCAO模型为例,观察了Platesome-DFO纳米制剂对大脑缺血再灌注损伤的治疗作用,确证了本发明制得的Platesome-DFO纳米颗粒,显著降低了缺血再灌注脑区的铁水平,使脑梗死体积降低了2.5倍,为缺血性脑中风的溶栓后治疗提供了新策略。
具体的,本发明的血小板-DFO脂质体纳米颗粒,粒径位于100-200nm之间;所述血小板-DFO脂质体纳米颗粒为三层结构,最内层是铁螯合剂DFO,其中间层为脂质体,由大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比(3-4):2:1制备而成,用以包裹最内层铁螯合剂DFO,最外层包裹血小板膜,DFO脂质体与血小板膜的比例为1 mL:1.0-2.0×109个血小板的膜。血小板-DFO脂质体纳米颗粒中,DFO含量为5-15mg/mL。
利用所述的血小板-DFO脂质体纳米颗粒,作为治疗缺血溶栓后的一种药物进行应用,用于治疗各种器官血管堵塞疏通后对周围组织造成损伤的治疗。如脑血管、心脏血管、肾脏血管等堵塞溶栓后的血液再灌注引起的铁水平增加,氧化应激增强造成的损伤。
所述的血小板-DFO脂质体纳米颗粒,作为治疗缺血溶栓后的一种药物进行应用,可制备成静脉注射液、胶囊、口服液、滴丸、喷鼻剂。
所述的血小板-DFO脂质体纳米颗粒的制备方法,包括以下步骤:
步骤一、血小板膜的制备
试剂配制:
HEPE 缓冲液(HEPE buffer):
按照质量比NaCl:KCl:HEPES:EGTA为1:(0.02-0.03):(0.1-0.2):(0.2-0.3)的比例溶解于水中,调节pH至7.0-8.0,制成HEPE 缓冲液;
洗涤缓冲液(wash buffer):
按照质量比NaCl:EDTA:dextrose:柠檬酸钠为1:(0.03-0.04):(1.0-1.2):(0.3-0.4)的比例溶解于水中,调节pH至7.0-8.0,制成洗涤缓冲液;
台式缓冲液(Tyrode’s buffer):
按照质量比NaCl:NaHCO3:KCl:Na2HPO4:MgCl2:HEPES为1:(0.1-0.2):(0.02-0.04):(0.005-0.007):(0.01-0.02):(0.3-0.4)的比例溶解于水中,之后按照体积比PEG:PMSF:水为1:1:10000的比例加入PEG和PMSF并调节pH至7.0-8.0,制成台式缓冲液,备用;
血小板膜的制备过程:
(1)选用成年大鼠或小鼠,通过心脏取血的方式取血,加入抗凝剂后将血液收集至管内;
(2)收集血液后0-4 h内处理并收集血小板,全血加HEPE buffer以10:1比例进一步抗凝;
(3)80-100 g离心,15-20 min,取上清得富含血小板的血浆;
(4)700-1000 g离心,15-20 min,取沉淀;
(5)加红细胞裂解液(5:1),低温裂解5-10 min,重复步骤(4);
(6)加入wash buffer重悬沉淀,重复步骤(4);
(7)用Tyrode’s buffer或水重悬沉淀,用计数仪对收集的血小板计数;
(8)反复冻融3次,-80℃-常温循环,超声破碎处理后得到血小板膜(PNV);
步骤二、Platesome-DFO的制备
(1)将大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比(3-4):2:1溶解在装有3-5mL无水乙醇的茄形瓶中,45-50 ℃水浴,转速60-70 r/min,旋蒸10-20 min,直至无水乙醇全部蒸出,且烧瓶底为均匀的薄膜;
(2)向茄形瓶内加入浓度20-50 mg/mL的 DFO生理盐水溶液1-2mL进行水化,同时加入3-6个玻璃珠,在超声清洗仪的帮助下水化2-5 min,直至瓶壁上的膜全部洗脱在溶液中,得到DFO脂质体(Liposome-DFO);
(3)将制备的脂质体用挤出器挤出后超滤,条件3000g,30min,加生理盐水再离心30min,再加盐水,离心50min,取出脂质体,加入步骤1制备的PNV(约含有1.0-2.0×109个血小板),用生理盐水重悬沉淀,之后用挤出器进行共挤出,挤出时依次通过400 nm、200 nm的滤膜,反复挤出后得到Platesome-DFO。
血小板-DFO脂质体纳米制颗粒的应用实验。
利用所述的血小板-DFO脂质体纳米颗粒,作为治疗缺血溶栓后的一种药物进行应用,用于治疗各种器官血管堵塞疏通后对周围组织造成损伤的治疗进行实验研究。将Platesome-DFO制备成静脉注射液、胶囊、口服液、滴丸、喷鼻剂任一剂型进行对比实验研究。
通过大脑中动脉内线栓阻断法 (Middle Cerebral Artery Occlusion,MCAO) 使小鼠脑缺血60min,之后拔出线栓,血流再灌注24h,建立小鼠I/R模型,模拟缺血性脑中风的溶栓治疗。设置Saline、DFO、Liposome-DFO、PNV和Platesome-DFO共5组制剂,在再灌注开始时,按照给药量15-25 mg DFO/kg体重的相对剂量,通过尾静脉注射对中风小鼠进行治疗。给药24h后,将小鼠麻醉,取脑,通过TTC(2,3,5-三苯基氯化四氮唑)染色计算不同组小鼠脑梗死体积。与对照组(Saline)相比,Platesome-DFO治疗后小鼠脑梗死体积显著下降,由35%-40%下降至15%-25%,而DFO、Liposome-DFO和PNV治疗并未明显改善I/R诱导的小鼠脑损伤。实验证实,用所述的血小板-DFO脂质体纳米颗粒,可以作为治疗缺血溶栓后的一种药物进行应用,用于治疗各种器官血管堵塞疏通后对周围组织造成损伤的治疗。
本发明取得的有益效果:
本发明通过将DFO脂质体与血小板膜共挤出,制备了Platesome-DFO纳米颗粒。对Platesome-DFO进行表征,证实其粒径均值在140nm左右,电位约-20.3 mV,透射电子显微镜分析发现Platesome-DFO粒子规整、分散均一稳定;对Platesome-DFO进行长期保存实验,验证了Platesome-DFO具有长期保存稳定性;体外药物释放实验,表明Platesome-DFO具有缓控释能力;蛋白免疫印迹验证Platesome-DFO含有血小板膜蛋白,保留了血小板膜的特性。利用小鼠的MACO模型,模拟缺血性脑中风的溶栓过程,通过尾静脉注射给药治疗后,利用体内成像技术,证实Platesome-DFO具有显著的缺血区靶向能力;利用电感耦合等离子体质谱技术,检测缺血再灌注脑区铁水平,发现与对照组(Saline组)、DFO溶液组(DFO组)、DFO脂质体组(Liposome-DFO组)、血小板膜组(PNV组)相比,Platesome-DFO能有效螯合缺血损伤区过量的铁。TTC染色实验表明Platesome-DFO能显著改善小鼠脑损伤。
附图说明
图1:Platesome-DFO粒径。
Platesome-DFO的粒径采用动态光散射技术测定。如图1所示,同时制备了PNV、Liposome-DFO和Platesome-DFO,其平均水合粒径为203.5±4.54 nm、166.9±2.02 nm和136.6±1.65 nm。Platesome-DFO相比于其他两组载体材料粒径更小,更有利于透过BBB。
图2:Platesome-DFO的zeta电位。
Zeta电位是表征分散系稳定性的重要指标。如图2所示,三种载体材料的平均电位分别为-21±1.66 mV、-10.2±1.08 mV和-20.3±1.46 mV。Platesome-DFO和PNV的电位接近,表明血小板膜成功包被了DFO脂质体。
图3:Platesome-DFO透射电镜图。
图3表明,本发明制备的Platesome-DFO纳米载体形貌为规整的球形囊泡,粒径大小均匀。
图4:Platesome-DFO长期保存稳定性检测。
纳米药物的长期保存在临床应用中十分重要,为验证Platesome-DFO是否能长期保持稳定,将制备好的Liposome-DFO和Platesome-DFO放置于4 ℃ PBS中保存,每隔1天用动态光散射仪检测载体材料的粒径。如图4所示,两组载体材料保存7天后粒径分别为162nm和135 nm左右,无明显变化。表明Platesome-DFO在7天内保存相对稳定。
图5:Platesome-DFO的体外释药曲线。
Liposome-DFO、Platesome-DFO制备完成后,分别设置pH=5.0和pH=7.4的PBS溶液模拟溶酶体环境和正常生理条件的pH。如图5所示,Liposome-DFO和Platesome-DFO在pH=7.4的PBS溶液中,4 h时分别累计释放了45.6 %和49.4 %,相应的在pH=5的PBS溶液中,分别累计释放了70.7 %和67.8 %,表明两组纳米载体在正常生理条件下,释放药物较缓慢,而在溶酶体酸性环境中能快速释放药物,具有调控释药速率的作用。
图6:Platesome-DFO血小板膜蛋白成分分析。
血小板膜表面含多种膜蛋白,膜蛋白的保持是决定Platesome-DFO能够靶向缺血区和免疫逃逸作用的关键。通过蛋白免疫印迹实验分别检测了血小板(PLT)、PNV、Liposome-DFO以及Platesome-DFO四组载体材料的膜蛋白。如图6所示,本方法合成的Platesome-DFO表面具有血小板膜特异的CD36、CD41、CD47蛋白,表明Platesome-DFO具备与血小板膜类似的生理功能。
图7:Platesome-Dir在体内靶向缺血损伤区。
为验证血小板膜制备的纳米体系能跨越BBB并靶向缺血区。分别用以上体系包被荧光染料Dir,制备了Liposome-Dir和Platesome-Dir,同时以Saline组为对照,将相同荧光含量的纳米材料经尾静脉注射至缺血性脑中风模型小鼠,24 h后取材,并用体内成像系统观察脑内荧光分布。如图7所示,Platesome-Dir在缺血区大量富集,且显著优于Liposome-Dir组,表明Platesome-Dir较Liposome-Dir具有更强的靶向能力。
图8:Platesome-DFO降低了脑梗死区铁水平。
铁过载是造成脑缺血再灌注损伤的主要原因之一。用Saline、DFO、Liposome-DFO、PNV和Platesome-DFO,对脑中风小鼠进行治疗后,用电感耦合等离子体质谱仪(ICP-MS)检测小鼠对照侧脑组织(Con)及缺血损伤区脑组织(I/R)铁水平的变化。如图8所示,Saline组中,与对照侧相比,I/R损伤侧铁含量显著升高,DFO、PNV及Liposome-DFO处理并未显著影响缺血损伤区铁含量,而Platesome-DFO处理使I/R侧铁含量恢复至与对照侧相当的水平。
图9:Platesome-DFO显著改善I/R诱导的小鼠脑损伤。
分别用Saline、DFO、Liposome-DFO、PNV和Platesome-DFO纳米药物治疗中风模型小鼠,24 h后用TTC染色检测脑梗死体积,如图9所示,TTC染料能将正常脑组织染成红色,梗死组织染成白色。Platesome-DFO与其他治疗组相比,能显著降低脑梗死区体积,说明Platesome-DFO对脑缺血再灌注的损伤具有明显的神经保护作用。
具体实施方式
以下实施例对本发明做进一步说明,但本发明的保护范围不限于此。
实施例1 Platesome-DFO纳米颗粒(包封率为12%)的制备
步骤一、血小板膜的制备
试剂配制:
HEPE 缓冲液(HEPE buffer):
按照质量比NaCl:KCl:HEPES:EGTA为1:(0.02-0.03):(0.1-0.2):(0.2-0.3)的比例溶解于水中,调节pH至7.0-8.0,制成HEPE 缓冲液;
洗涤缓冲液(wash buffer):
按照质量比NaCl:EDTA:dextrose:柠檬酸钠为1:(0.03-0.04):(1.0-1.2):(0.3-0.4)的比例溶解于水中,调节pH至7.0-8.0,制成洗涤缓冲液;
台式缓冲液(Tyrode’s buffer):
按照质量比NaCl:NaHCO3:KCl:Na2HPO4:MgCl2:HEPES为1:(0.1-0.2):(0.02-0.04):(0.005-0.007):(0.01-0.02):(0.3-0.4)的比例溶解于水中,之后按照体积比PEG:PMSF:水为1:1:10000的比例加入PEG和PMSF并调节pH至7.0-8.0,制成台式缓冲液;
制备过程:
(1)选用成年大鼠或小鼠,通过心脏取血的方式取血,加入抗凝剂后将血液收集至管内;
(2)收集血液后0-4 h内处理并收集血小板,全血加HEPE buffer以10:1比例进一步抗凝;
(3)80-100 g离心,15-20 min,取上清得富含血小板的血浆;
(4)700-1000 g离心,15-20 min,取沉淀;
(5)加红细胞裂解液(5:1),低温裂解5-10 min,重复步骤(4);
(6)加入wash buffer重悬沉淀,重复步骤(4);
(7)用Tyrode’s buffer或水重悬沉淀,用计数仪对收集的血小板计数;
(8)反复冻融3次,-80℃-常温循环,超声破碎处理后得到血小板膜(PNV);
步骤二、Platesome-DFO的制备
(1)将大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比3.8:2:1溶解在装有4 mL无水乙醇的茄形瓶中,45℃水浴,转速60r/min,旋蒸15 min,直至无水乙醇全部蒸出,且烧瓶底为均匀的薄膜。
(2)向茄形瓶内加入浓度50 mg/mL的 DFO生理盐水溶液2mL进行水化,同时加入5个玻璃珠,在超声清洗仪的帮助下水化5 min,直至瓶壁上的膜全部洗脱在溶液中,得到DFO脂质体(Liposome-DFO)。
(3)将制备的脂质体用挤出器挤出后超滤,条件3000g,30min,加生理盐水再离心30min,再加盐水,离心50min,取出脂质体,加入PNV(约含有2.0×109个血小板),用生理盐水重悬沉淀,之后用挤出器进行共挤出,挤出时依次通过400 nm、200 nm的滤膜,反复挤出后得到Platesome-DFO。所得Platesome-DFO包封率为12%。
实施例2 一种血小板-DFO脂质体纳米颗粒(包封率为11%)的制备
步骤一、血小板膜的制备
制备方法与实施例1相同。
步骤二、Platesome-DFO的制备
(1)将大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比4:2:1溶解在装有4 mL无水乙醇的茄形瓶中,45℃水浴,转速60r/min,旋蒸15 min,直至无水乙醇全部蒸出,且烧瓶底为均匀的薄膜。
(2)向茄形瓶内加入浓度50 mg/mL的 DFO生理盐水溶液2mL进行水化,同时加入5个玻璃珠,在超声清洗仪的帮助下水化5 min,直至瓶壁上的膜全部洗脱在溶液中,得到DFO脂质体(Liposome-DFO)。
(3)将制备的脂质体用挤出器挤出后超滤,条件3000g,30min,加
生理盐水再离心30min,再加盐水,离心50min,取出脂质体,加入PNV(约含有1.5×109个血小板),用生理盐水重悬沉淀,之后用挤出器进行共挤出,挤出时依次通过400 nm、200 nm的滤膜,反复挤出后得到Platesome-DFO。所得Platesome-DFO包封率为11%。
实施例3 一种血小板-DFO脂质体纳米颗粒(包封率为9.5%)的制备
步骤一、血小板膜的制备
制备方法与实施例1相同。
步骤二、Platesome-DFO的制备
(1)将大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比3:2:1溶解在装有4 mL无水乙醇的茄形瓶中,45℃水浴,转速70r/min,旋蒸15 min,直至无水乙醇全部蒸出,且烧瓶底为均匀的薄膜。
(2)向茄形瓶内加入浓度20 mg/mL的 DFO生理盐水溶液2mL进行水化,同时加入5个玻璃珠,在超声清洗仪的帮助下水化5 min,直至瓶壁上的膜全部洗脱在溶液中,得到DFO脂质体(Liposome-DFO)。
(3)将制备的脂质体用挤出器挤出后超滤,条件3000g,30min,加生理盐水再离心30min,再加盐水,离心50min,取出脂质体,加入PNV(约含有1.5×109个血小板),用生理盐水重悬沉淀,之后用挤出器进行共挤出,挤出时依次通过400 nm、200 nm的滤膜,反复挤出后得到Platesome-DFO。所得Platesome-DFO包封率为9.5%。
实施例4 Platesome-DFO对缺血性脑中风溶栓后损伤的治疗作用
方案1:与对照组相比,Platesome-DFO治疗使小鼠脑梗死体积减少2.5倍
(1) 按照实施例1中的方法制备Platesome-DFO。
(2) 通过大脑中动脉内线栓阻断法 (Middle Cerebral Artery Occlusion,MCAO) 使小鼠脑缺血60min,之后拔出线栓,血流再灌注24h,建立小鼠I/R模型,模拟人类缺血性脑中风溶栓后的血液再灌注。
(3)设置Saline、DFO、Liposome-DFO、PNV和Platesome-DFO共5组制剂,在脑缺血再灌注时,通过尾静脉注射各组药物,按药量为25 mg DFO/kg体重的相对剂量进行治疗。
(4)再灌注24 h后,用5 %水合氯醛麻醉,断头取脑,脑槽内将鼠脑切片后置于2 %TTC染液中,在37 ℃恒温培养箱中避光染色7 min。
(5)拍照并计算梗死体积,梗死体积百分比=(对侧半球体积-同侧半球未梗死区域体积)/对侧梗死区半球体积×100 %。Saline、DFO、Liposome-DFO、PNV和Platesome-DFO组小鼠脑梗死体积分别为:40%,38%,32%,38%,16%,与对照组相比Platesome-DFO治疗后使梗死体积减小2.5倍。
方案2:与对照组相比,Platesome-DFO治疗使小鼠脑梗死体积减少1.65倍
(1)按照实施例1中的方法制备Platesome-DFO。
(2)通过大脑中动脉内线栓阻断法 (Middle Cerebral Artery Occlusion,MCAO)使小鼠脑缺血60min,之后拔出线栓,血流再灌注24h,建立小鼠I/R模型。
(3)设置Saline、DFO、Liposome-DFO、PNV和Platesome-DFO共5组纳米药物治疗中风小鼠,再灌注时,通过尾静脉注射各组药物,按药量为15 mg DFO/kg体重的相对剂量进行治疗。
(4)再灌注24 h后,用5 %水合氯醛麻醉,断头取脑,脑槽内将鼠脑切片后置于2 %TTC染液中,在37 ℃恒温培养箱中避光染色7 min。
(5)拍照并计算梗死体积,梗死体积百分比=(对侧半球体积-同侧半球未梗死区域体积)/对侧梗死区半球体积×100 %。Saline、DFO、Liposome-DFO、PNV和Platesome-DFO组小鼠脑梗死体积分别为:38%,36%,30%,36%,23%,与对照组相比Platesome-DFO治疗后使梗死体积减小1.65倍。
Claims (4)
1.一种血小板-DFO脂质体纳米颗粒,其特征在于:其为三层结构,最内层是铁螯合剂DFO,其中间层为脂质体,由大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比(3-4):2:1制备而成,用以包裹最内层铁螯合剂DFO,最外层包裹血小板膜,DFO脂质体与血小板膜的比例为1 mL:1.0-2.0×109个血小板的膜,血小板-DFO脂质体纳米颗粒中,DFO含量为5-15mg/mL。
2.根据权利要求1所述的一种血小板-DFO脂质体纳米颗粒,其特征在于:粒径100~200nm。
3.一种如权利要求1或2所说的血小板-DFO脂质体纳米颗粒的制备方法,其特征在于包括以下步骤:
步骤一、血小板膜的制备
试剂配制:
HEPE 缓冲液(HEPE buffer):
按照质量比NaCl:KCl:HEPES:EGTA为1:(0.02-0.03):(0.1-0.2):(0.2-0.3) 的比例溶解于水中,调节pH至7.0-8.0,制成HEPE 缓冲液;
洗涤缓冲液(wash buffer):
按照质量比NaCl:EDTA:dextrose:柠檬酸钠为1:(0.03-0.04):(1.0-1.2):(0.3-0.4)的比例溶解于水中,调节pH至7.0-8.0,制成洗涤缓冲液;
台式缓冲液(Tyrode’s buffer):
按照质量比NaCl:NaHCO3:KCl:Na2HPO4:MgCl2:HEPES为1:(0.1-0.2):(0.02-0.04):(0.005-0.007):(0.01-0.02):(0.3-0.4)的比例溶解于水中,之后按照体积比PEG:PMSF:水为1:1:10000的 比例加入PEG和PMSF并调节pH至7.0-8.0,制成台式缓冲液,备用;
制备过程:
(1)选用成年大鼠或小鼠,通过心脏取血的方式取血,加入抗凝剂后将血液收集至管内;
(2)收集血液后0-4 h内处理并收集血小板,全血加HEPE buffer以10:1比例进一步抗凝;
(3)80-100 g离心,15-20 min,取上清得富含血小板的血浆;
(4)700-1000 g离心,15-20 min,取沉淀;
(5)加红细胞裂解液(5:1),低温裂解5-10 min,重复步骤(4);
(6)加入wash buffer重悬沉淀,重复步骤(4);
(7)用Tyrode’s buffer或水重悬沉淀,用计数仪对收集的血小板计数;
(8)反复冻融3次,-80℃-常温循环,超声破碎处理后得到血小板膜(PNV);
步骤二、Platesome-DFO的制备
(1)将大豆卵磷脂:胆固醇:mPEG-DSPE-2000按质量比(3-4):2:1溶解在装有3-5 mL无水乙醇的茄形瓶中,45-50 ℃水浴,转速60-70 r/min,旋蒸10-20 min,直至无水乙醇全部蒸出,且烧瓶底为均匀的薄膜;
(2)向茄形瓶内加入浓度20-50 mg/mL的 DFO生理盐水溶液1-2mL进行水化,同时加入3-6个玻璃珠,在超声清洗仪的帮助下水化2-5 min,直至瓶壁上的膜全部洗脱在溶液中,得到DFO脂质体(Liposome-DFO);
(3)将制备的脂质体用挤出器挤出后超滤,条件3000g,30min,加生理盐水再离心30min,再加盐水,离心50min,取出脂质体,加入步骤一制备的PNV(约含有1.0-2.0×109个血小板),用生理盐水重悬沉淀,之后用挤出器进行共挤出,挤出时依次通过400 nm、200 nm的滤膜,反复挤出后得到Platesome-DFO成品。
4.一种如权利要求1或2所述的的血小板-DFO脂质体纳米颗粒的应用,其特征在于,制备成静脉注射液、胶囊、口服液、滴丸、喷鼻剂任意一种,作为治疗缺血溶栓后的一种药物应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111324986.4A CN113952317A (zh) | 2021-11-10 | 2021-11-10 | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 |
CN202310692185.6A CN116712410A (zh) | 2021-11-10 | 2021-11-10 | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111324986.4A CN113952317A (zh) | 2021-11-10 | 2021-11-10 | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310692185.6A Division CN116712410A (zh) | 2021-11-10 | 2021-11-10 | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113952317A true CN113952317A (zh) | 2022-01-21 |
Family
ID=79469923
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111324986.4A Pending CN113952317A (zh) | 2021-11-10 | 2021-11-10 | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 |
CN202310692185.6A Pending CN116712410A (zh) | 2021-11-10 | 2021-11-10 | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310692185.6A Pending CN116712410A (zh) | 2021-11-10 | 2021-11-10 | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN113952317A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010033860A1 (en) * | 1999-12-30 | 2001-10-25 | Gwathmey Judith K. | Iron chelator delivery system |
CN109364263A (zh) * | 2018-10-31 | 2019-02-22 | 南京医科大学 | 一种功能化的血小板仿生智能载体及其抗缺血性脑卒中应用 |
CN109432048A (zh) * | 2018-11-22 | 2019-03-08 | 东华大学 | 一种血小板膜包裹载药多孔纳米颗粒及其制备方法 |
US20200085875A1 (en) * | 2017-04-20 | 2020-03-19 | North Carolina State University | Platelet vesicle-engineered cells for targeted tissue repair |
CN111789958A (zh) * | 2020-08-26 | 2020-10-20 | 山东大学 | 一种基于血小板膜碎片的仿生纳米制剂及其制备方法和应用 |
-
2021
- 2021-11-10 CN CN202111324986.4A patent/CN113952317A/zh active Pending
- 2021-11-10 CN CN202310692185.6A patent/CN116712410A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010033860A1 (en) * | 1999-12-30 | 2001-10-25 | Gwathmey Judith K. | Iron chelator delivery system |
US20200085875A1 (en) * | 2017-04-20 | 2020-03-19 | North Carolina State University | Platelet vesicle-engineered cells for targeted tissue repair |
CN109364263A (zh) * | 2018-10-31 | 2019-02-22 | 南京医科大学 | 一种功能化的血小板仿生智能载体及其抗缺血性脑卒中应用 |
CN109432048A (zh) * | 2018-11-22 | 2019-03-08 | 东华大学 | 一种血小板膜包裹载药多孔纳米颗粒及其制备方法 |
CN111789958A (zh) * | 2020-08-26 | 2020-10-20 | 山东大学 | 一种基于血小板膜碎片的仿生纳米制剂及其制备方法和应用 |
Non-Patent Citations (6)
Title |
---|
YU-WENWU 等: ""Smart blood cell and microvesicle-based Trojan horse drug"", 《TRANSFUSION AND APHERESIS SCIENCE》 * |
冯毅等: ""细胞膜包被纳米粒的合成及应用研究进展"", 《山东医药》 * |
张茹等: ""甲磺酸去铁胺纳米脂质体的制备、理化性质及细胞活力研究"", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 * |
徐剑培等: ""基于血小板及其膜的仿生递药系统研究进展"", 《中国药科大学学报》 * |
王学锋等主编: "《血栓与止血的检测及应用》", 31 May 2002, 上海:上海世界图书出版公司 * |
邱思仪等: ""基于血小板膜的纳米给药系统研究进展"", 《重庆医科大学学报》 * |
Also Published As
Publication number | Publication date |
---|---|
CN116712410A (zh) | 2023-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gou et al. | Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis | |
CN106177986B (zh) | 一种脂质体-聚合物载药纳米粒子及其制备方法和应用 | |
Sun et al. | Photodynamic therapy produces enhanced efficacy of antitumor immunotherapy by simultaneously inducing intratumoral release of sorafenib | |
WO2018177420A1 (zh) | 一种生物膜包载药物纳米晶体的制备方法及其用途 | |
Yu et al. | Rescuing ischemic stroke by biomimetic nanovesicles through accelerated thrombolysis and sequential ischemia-reperfusion protection | |
CN109364263B (zh) | 一种功能化的血小板仿生智能载体及其抗缺血性脑卒中应用 | |
WO2018041261A1 (zh) | 一种肿瘤治疗药物 | |
Alahri et al. | Theranostic applications of metal–organic frameworks (MOFs)-based materials in brain disorders: recent advances and challenges | |
CN112516109B (zh) | 一种基于间充质干细胞的融合癌细胞膜仿生纳米粒及其制备方法 | |
CN112716915A (zh) | 仿生纳米载体及其在制备脑胶质瘤治疗药物的应用 | |
CN112823811A (zh) | 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法 | |
Yao et al. | TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma | |
Liu et al. | Brain‐targeting drug delivery systems | |
Xie et al. | Bacteria-propelled microtubular motors for efficient penetration and targeting delivery of thrombolytic agents | |
CN114569576B (zh) | 一种脑靶向红细胞膜包裹丹酚酸b纳米粒、制备方法及其应用 | |
Li et al. | Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: In vitro and in vivo evaluation | |
Badar et al. | Nano based drug delivery systems: present and future prospects | |
Ellis-Behnke | Nano neurology and the four P's of central nervous system regeneration: preserve, permit, promote, plasticity | |
Wang et al. | Blood cells as supercarrier systems for advanced drug delivery | |
WO2019237884A1 (zh) | 一种淀粉样蛋白β短肽介导的脑靶向递送系统及其制备方法和用途 | |
CN108143719B (zh) | 一种携载多肽的纳米脂质体及其制备方法和应用 | |
Zhao et al. | The application of nanomedicine in clinical settings | |
CN113952317A (zh) | 一种血小板-dfo脂质体纳米颗粒、制备方法和应用 | |
Huang et al. | Multi-enzyme mimetic iridium nanozymes-based thrombus microenvironment-modulated nanoplatform for enhanced thrombolytic therapy | |
Shen et al. | High rapamycin-loaded hollow mesoporous Prussian blue nanozyme targets lesion area of spinal cord injury to recover locomotor function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220121 |